Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk Strategic Aspirations Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021 51
Cash flow statement
for the year ended 31 December
DKK million
Cash flow statement
Net profit
Adjustment of non-cash items:
Note
2021
2020
2019
DKK million
Note
2021
47,757
42,138 38,951
Purchase of treasury shares
Dividends paid
4.2
2020
(19,447) (16,855) (15,334)
2019
4.1
(21,517) (20,121) (19,409)
Proceeds from borrowings
4.5
Income taxes in the income statement
2.6
11,323
10,992
9,602
Repayment of borrowings
4.5
22,160
(6,689)
Depreciation, amortisation and impairment losses
3.1
6,025
5,753
5,661
Net cash used in financing activities
81
(950) (822)
(25,493) (32,244) (35,484)
5,682
Other non-cash items
4.7
13,009
7,849
7,032
Net cash generated from activities
(2,098)
(2,729)
(211)
Change in working capital
4.8
(8,656)
(4,353)
(3,388)
Interest received
241
100
64
Interest paid
(261)
Income taxes paid
2.6
(14,438)
(422) (204)
(10,106) (10,936)
Cash and cash equivalents at the beginning of the year
Exchange gains/(losses) on cash and cash equivalents
Cash and cash equivalents at the end of the year
12,226
15,411
15,629
591
4.6
10,719
(456)
12,226
(7)
15,411
Net cash generated from operating activities
55,000
51,951 46,782
Purchase of intangible assets
3.1
(1,050)
(16,256)
(2,299)
Proceeds from sale of property, plant and equipment
7
4
Purchase of property, plant and equipment
3.1
(6,335)
(5,825)
(8,932)
Cash used for acquisition of businesses
5.3
(18,283)
Proceeds from other financial assets
Purchase of other financial assets
12
21
148
(350)
(4)
Purchase of marketable securities
(7,109)
Sale of marketable securities
1,172
।।
Investment in associated companies
5.4
(392)
(97)
Proceeds from the divestment of Group and
associated companies
(3)
Dividend received from associated companies
5.4
4
18
20
Net cash used in investing activities
(31,605)
(22,436)
(11,509)View entire presentation